The method relates to humanized antibodies that bind an epitope peptide Aβ having amino acids between aminoacids 13 and 28 and to prophylactic or therapeutic treatment of conditions characterized by formation of β-amyloid such as Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy. More definite, the invention relates to using humanized monoclonal antibodies to sequester the amyloid beta peptide A β in plasma, brain or cerebrospinal fluid to prevent accumulation or to reverse deposition of the Aβ peptide within the brain and in the cerebrovasculature and to improve cognition.
HUMANIZED ANTIBODIES THAT SEQUESTER Aβ PEPTIDE